Suven Life Sciences Ltd

- Suven Life Sciences plans to raise new sources of income within one year, potentially through monetization, strategic partners, or an IPO. - Management indicates the need for raising money within the next 12 months to continue activities; otherwise, funds may run out in 15-18 months. - No specific timeline or definite plans for new fundraising through debt or equity were disclosed, but several options (monetization, strategic investor, IPO) are under consideration. - Suven Pharma currently has working capital debt of about Rs. 32-35 crore and no long-term debt; no mention of immediate new debt raising. - Monetization opportunities for Suven Neurosciences through a US IPO are planned about 2.5 years from now. - Strategic investor interest is possible post-demerger, but no active search or commitment announced yet.

- Suven Pharma has a total planned CAPEX of Rs. 320 crore, with Rs. 160 crore already spent and the balance expected to be spent by the end of FY20 (Pages 5-6). - For FY21, only replacement CAPEX of Rs. 50 crore is planned; no major new CAPEX is planned currently (Page 6). - The Rs. 320 crore CAPEX spans specialty chemicals, intermediates, formulation, and niche API (backward integration for internal and CRAMS customers) but not large-scale API commercial production (Pages 11-15). - Capacity expansion is focused on reactor capacity (about 300 kiloliters), supporting a mix-and-match batch production model rather than fixed product capacity (Page 11). - Management bandwidth is planned to be expanded, with a senior executive (COO level) recruitment expected within 3-4 months to support CRAMS expansion (Page 4). - Strategic investors could be considered post-demerger in the CRAMS business, but no active search has started (Page 7).

- Suven Pharma expects 15-20% growth in revenue for FY21 and beyond, based on expanded activities and capacities. - Growth outlook is driven by a mix of contract manufacturing, specialty chemicals, new ANDA filings, and commercial CRAMS. - The company acknowledges variability in quarter-to-quarter performance but maintains confidence in overall annual growth. - FROM FY21 onwards, growth is expected to improve further with new infrastructure and expanded activities. - The capacity utilization is effectively 100%, with a mix-and-match product approach allowing flexibility. - Long-term growth potential is positive, though exact segmental contributions are not disclosed. - Management emphasizes value over volume, focusing on high-margin products rather than sheer volume increases. - Growth guidance is based on past performance, project pipeline, and gut feeling but with uncertainty acknowledged.

- Suven Pharma expects 15-20% revenue growth in the next year (FY21), based on expanded activities and capacities. - EBITDA margins are anticipated to be maintained around 40% on average, despite some quarter-to-quarter fluctuations. - Growth will be driven by multiple segments including specialty chemicals, ANDA portfolio, commercial CRAMS, with contributions varying quarterly. - The growth guidance is based on past performance, current projects, and gut feeling, with no full visibility or guarantees. - Suven Life Sciences is expected to seek new income sources within a year, possibly through monetization or IPO, indicating potential for future earnings growth there. - Tax rate for Suven Pharma for the next year is expected to be 25%. - No detailed segmental revenue or product-wise margin guidance will be shared going forward. Overall, management projects steady growth with maintained margins, driven by ongoing expanded business activities.

- Suven Pharma's commercial supply fluctuates with product demand, making it difficult to gauge a fixed order book or capacity utilization on a monthly basis. (Page 11) - Capacity utilization is effectively 100% in terms of mix and match product manufacturing, but not continuously occupied by a single product. (Page 11) - Management expects 15-20% growth next year based on the current number of projects and past performance, indicating a healthy order pipeline. (Page 12) - Ongoing contingency planning for raw material supply disruptions is active, with daily updates to customers, implying active order management. (Page 16) - Phase 2 proof-of-concept clinical trial for G-3031 is progressing slower; results expected by March 2021 which will influence monetization opportunities. (Page 19) - No direct quantification of current pending orders or orderbook was disclosed in the transcript.